NEWS

• Bioclinica, Inc. To Demonstrate Technology-Enhanced Capabilities At Upcoming Global Industry Events

  BioClinica, Inc. a global provider of clinical trial management solutions, recently announced that members of its team will attend, participate in, and speak at several upcoming industry conferences in April, May, and June.

• DiaMedica Successfully Completes DM-199 cGMP Manufacturing And Pre-Clinical Toxicology Safety Studies

  DiaMedica (TSX VENTURE:DMA) has successfully completed cGMP manufacturing of DM-199 to be utilized in upcoming clinical trials.

• ERT Expands Corporate Presence In Japan

  ERT, a global technology-driven provider of health outcomes research services to biopharmaceutical organizations, medical device companies and contract research organizations (CROs), recently announced significant milestones that reinforce its position as a leading eClinical trial solutions provider in Japan.

• A Collaboration For More Effective Centralized Cardiac Safety Services

  Spaulding Clinical Research Announces Collaboration with Blinded Diagnostics for centralized cardiac safety services for select pharmaceutical clients.

• Spaulding Clinical Research Announces Collaboration With Blinded Diagnostics For Centralized Cardiac Safety Services For Select Pharmaceutical Clients

  Spaulding Clinical Research has agreed to offer ECG services using the new Spaulding webECG Diagnostic ECG Management system for late stage clinical trials through Blinded Diagnostics.

• ERT Introduces An Enhanced Platform To Streamline Data Collection, Analysis And Processing In Clinical Trials

  ERT, a global technology-driven provider of health outcomes services to biopharmaceutical organizations, medical device companies and contract research organizations (CROs), recently announced the launch of an enhanced clinical research workflow technology designed to streamline data collection, analysis and processing in clinical trials. 

• Phase 3 MISSION Trial Of Nexavar (Sorafenib) In Patients With Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint Of Improving Overall Survival

  Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that a Phase 3 trial evaluating Nexavar^® (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.

• iCardiac Technologies’ Growth Accelerates Revenue Growth Exceeds 140% Supported By Expansion Of Operations

  iCardiac Technologies, Inc., a provider of next  generation cardiac core lab services, announced recently it has recorded another increase in  its growth rate.

• ERT And UCLA Initiate Innovative Pilot Program For Chronically Ill Patients ERT, a global technology-driven provider of health outcomes services and customizable medical devices to biopharmaceutical sponsors and Contract Research Organizations (CROs), announces the launch of the CLEAR Study in collaboration with UCLA, an innovative program to help patients suffering from Chronic Obstructive Pulmonary Disease (COPD).
• Achillion Reports Clinical Data On Portfolio Of Protease Inhibitors Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported new clinical trial results on its portfolio of protease inhibitors including: Phase 2 interim 12-week treatment results with ACH-1625 for the treatment of genotype 1 treatment-naive hepatitis C virus (HCV), exploratory data on ACH-1625 for the treatment of HCV genotype 3, and initial proof-of-concept data for ACH-2684.
• The Cardiovascular Research Foundation And The Angiographic Core Laboratory Of Harvard Medical Faculty Physicians At Beth Israel Deaconess Medical Center, Inc. Announce CRFiCOR, A Collaborative Alliance To Enhance Patient Care The Angiographic and Imaging Core Laboratories of the Clinical Trials Center (CTC) at the Cardiovascular Research Foundation (CRF) in New York have formed a collaborative alliance with the Angiographic Core Laboratory of Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Inc. (HFMP).
• Spaulding Clinical Announces New Strategic Partnership With Frontage Laboratories, Inc. Frontage Laboratories, Inc., a global full-service Clinical Research Organization with facilities in the US and China, and Spaulding Clinical Research, LLC, a US-based, leading-edge Clinical Pharmacology Unit, ECG Core Lab, and Medical Device Manufacturer have entered into a strategic partnership agreement.
• Spaulding Clinical Announces Strategic Partnership With Clinigene International, India For Providing Comprehensive Early Clinical Solutions To Pharmaceutical And Biotech Clients Clinigene International Limited, an India-based Central and Bioanalytical Laboratory and Phase I-IV Clinical Research Organization, and Spaulding Clinical Research, LLC, US-based leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer, announce a strategic partnership agreement.
• Spaulding Clinical Announces New Joint Partnership For Global Studies With Eurofins Optimed Clinical Research Eurofins Optimed Clinical Research, an experienced European clinical research service provider and Spaulding Clinical Research, LLC., US-based, leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer, announce a joint partnership agreement.